Literature DB >> 25886922

Implementation and Operational Research: Maternal Combination Antiretroviral Therapy Is Associated With Improved Retention of HIV-Exposed Infants in Kinshasa, Democratic Republic of Congo.

Lydia Feinstein1, Andrew Edmonds, Vitus Okitolonda, Stephen R Cole, Annelies Van Rie, Benjamin H Chi, Papy Ndjibu, Jean Lusiama, Jean L Chalachala, Frieda Behets.   

Abstract

BACKGROUND: Programs to prevent mother-to-child HIV transmission are plagued by loss to follow-up (LTFU) of HIV-exposed infants. We assessed if providing combination antiretroviral therapy (cART) to HIV-infected mothers was associated with reduced LTFU of their HIV-exposed infants in Kinshasa, DR Congo.
METHODS: We constructed a cohort of mother-infant pairs using routinely collected clinical data. Maternal cART eligibility was based on national guidelines in effect at the time. Infants were considered LTFU after 3 failed tracking attempts after a missed visit or if more than 6 months passed since they were last seen in clinic. Statistical methods accounted for competing risks (eg, death).
RESULTS: A total of 1318 infants enrolled at a median age of 2.6 weeks (interquartile range: 2.1-6.9), at which point 24% of mothers were receiving cART. Overall, 5% of infants never returned to care after enrollment and 18% were LTFU by 18 months. The 18-month cumulative incidence of LTFU was 8% among infants whose mothers initiated cART by infant enrollment and 20% among infants whose mothers were not yet on cART. Adjusted for baseline factors, infants whose mothers were not on cART were over twice as likely to be LTFU, with a subdistribution hazard ratio of 2.75 (95% confidence limit: 1.81 to 4.16). The association remained strong regardless of maternal CD4 count at infant enrollment.
CONCLUSIONS: Increasing access to cART for pregnant women could improve retention of HIV-exposed infants, thereby increasing the clinical and population-level impacts of prevention of mother-to-child HIV transmission interventions and access to early cART for HIV-infected infants.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25886922      PMCID: PMC4506694          DOI: 10.1097/QAI.0000000000000644

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  20 in total

1.  Heterogeneous and decreasing HIV prevalence among women seeking antenatal care in Kinshasa, Democratic Republic of Congo.

Authors:  Frieda Behets; Andrew Edmonds; François Kitenge; François Crabbé; Marie Laga
Journal:  Int J Epidemiol       Date:  2010-05-07       Impact factor: 7.196

Review 2.  Use of multiple imputation in the epidemiologic literature.

Authors:  Mark A Klebanoff; Stephen R Cole
Journal:  Am J Epidemiol       Date:  2008-06-30       Impact factor: 4.897

3.  Addressing poor retention of infants exposed to HIV: a quality improvement study in rural Mozambique.

Authors:  Philip J Ciampa; José A Tique; Nilton Jumá; Mohsin Sidat; Troy D Moon; Russell L Rothman; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2012-06-01       Impact factor: 3.731

4.  Socio-demographic factors associated with loss to follow-up of HIV-infected women attending a private sector PMTCT program in Maharashtra, India.

Authors:  Mayuri Panditrao; Shrinivas Darak; Vinay Kulkarni; Sanjeevani Kulkarni; Ritu Parchure
Journal:  AIDS Care       Date:  2011-05

5.  Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV.

Authors:  Pierre M Barker; Wendy Mphatswe; Nigel Rollins
Journal:  J Acquir Immune Defic Syndr       Date:  2011-02-01       Impact factor: 3.731

6.  Exploring socio-economic conditions and poor follow-up rates of HIV-exposed infants in Johannesburg, South Africa.

Authors:  S A Jones; G G Sherman; C A Varga
Journal:  AIDS Care       Date:  2005-05

7.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

8.  Women's reasons for not participating in follow up visits before starting short course antiretroviral prophylaxis for prevention of mother to child transmission of HIV: qualitative interview study.

Authors:  Thomas M Painter; Kassamba L Diaby; Danielle M Matia; Lillian S Lin; Toussaint S Sibailly; Moïse K Kouassi; Ehounou R Ekpini; Thierry H Roels; Stefan Z Wiktor
Journal:  BMJ       Date:  2004-09-04

9.  Predictors of successful early infant diagnosis of HIV in a rural district hospital in Zambézia, Mozambique.

Authors:  Rebecca E Cook; Philip J Ciampa; Mohsin Sidat; Meridith Blevins; Janeen Burlison; Mario A Davidson; Jorge A Arroz; Alfredo E Vergara; Sten H Vermund; Troy D Moon
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.771

10.  Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis.

Authors:  Gilles Van Cutsem; Nathan Ford; Katherine Hildebrand; Eric Goemaere; Shaheed Mathee; Musaed Abrahams; David Coetzee; Andrew Boulle
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

View more
  8 in total

1.  Early Antiretroviral Therapy Initiation and Mortality Among Infants Diagnosed With HIV in the First 12 Weeks of Life: Experiences From Kinshasa, DR Congo and Blantyre, Malawi.

Authors:  Anna Sheahan; Lydia Feinstein; Queen Dube; Andrew Edmonds; Chawanangwa Mahebere Chirambo; Emily Smith; Frieda Behets; Robert Heyderman; Annelies Van Rie
Journal:  Pediatr Infect Dis J       Date:  2017-07       Impact factor: 2.129

2.  Assessing Option B+ retention and infant follow-up in Lilongwe, Malawi.

Authors:  Blake M Hauser; William C Miller; Hannock Tweya; Colin Speight; Tiwonge Mtande; Sam Phiri; L M Ball; Mina C Hosseinipour; Irving F Hoffman; Nora E Rosenberg
Journal:  Int J STD AIDS       Date:  2017-07-27       Impact factor: 1.359

3.  12-month outcomes of HIV-infected infants identified at birth at one maternity site in Johannesburg, South Africa: an observational cohort study.

Authors:  Karl-Günter Technau; Renate Strehlau; Faeezah Patel; Stephanie Shiau; Megan Burke; Martie Conradie; Gillian Sorour; Gayle G Sherman; Ashraf Coovadia; Pamela M Murnane; Elaine J Abrams; Louise Kuhn
Journal:  Lancet HIV       Date:  2018-11-08       Impact factor: 12.767

4.  Implementation and Operational Research: Decentralization Does Not Assure Optimal Delivery of PMTCT and HIV-Exposed Infant Services in a Low Prevalence Setting.

Authors:  Andrew Edmonds; Lydia Feinstein; Vitus Okitolonda; Deidre Thompson; Bienvenu Kawende; Frieda Behets
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

5.  Practical recommendations for reporting Fine-Gray model analyses for competing risk data.

Authors:  Peter C Austin; Jason P Fine
Journal:  Stat Med       Date:  2017-09-15       Impact factor: 2.373

6.  Firth's Logistic Regression of Interruption in Treatment before and after the Onset of COVID-19 among People Living with HIV on ART in Two Provinces of DRC.

Authors:  Gulzar H Shah; Gina D Etheredge; Jessica S Schwind; Lievain Maluantesa; Kristie C Waterfield; Astrid Mulenga; Osaremhen Ikhile; Elodie Engetele; Elizabeth Ayangunna
Journal:  Healthcare (Basel)       Date:  2022-08-12

7.  Factors Associated with Retention of HIV Patients on Antiretroviral Therapy in Care: Evidence from Outpatient Clinics in Two Provinces of the Democratic Republic of the Congo (DRC).

Authors:  Gulzar H Shah; Gina D Etheredge; Lievain Maluentesa Nkuta; Kristie C Waterfield; Osaremhen Ikhile; John Ditekemena; Bossiky Ngoy Belly Bernard
Journal:  Trop Med Infect Dis       Date:  2022-09-05

8.  HIV transmission and retention in care among HIV-exposed children enrolled in Malawi's prevention of mother-to-child transmission programme.

Authors:  Andreas D Haas; Joep J van Oosterhout; Lyson Tenthani; Andreas Jahn; Marcel Zwahlen; Malango T Msukwa; Mary-Ann Davies; Kali Tal; Nozgechi Phiri; Adrian Spoerri; Frank Chimbwandira; Matthias Egger; Olivia Keiser
Journal:  J Int AIDS Soc       Date:  2017-09-04       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.